PedAM
Pediatric Disease Annotations & Medicines
| Disease | artery disease |
| Phenotype | C0149931|migraine |
| Sentences | 5 |
| PubMedID- 21631478 | Antagonism of calcitonin gene-related peptide, which does not appear to cause vasoconstriction, may allow for treatment of migraine in patients with coronary artery disease. |
| PubMedID- 25206386 | Indeed, in 2012, a randomized clinical trial found that a calcitonin gene-related peptide receptor antagonist was well tolerated in the treatment of migraine in patients with coronary artery disease[15]. |
| PubMedID- 22406987 | The new acute drug, telcagepant, a calcitonin gene-related peptide (cgrp) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. |
| PubMedID- 22221076 | Conclusion: the study was underpowered due to enrollment difficulties and did not demonstrate a significant efficacy difference between telcagepant and placebo for the treatment of a migraine attack in patients with stable coronary artery disease. |
| PubMedID- 23602119 | Recent data suggest that migraine is also associated with coronary artery disease. |
Page: 1